Bicara Therapeutics Inc.

Contributing Author

Recent Articles by Bicara Therapeutics Inc.

7 hours	Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12 BCAX GlobeNewswire
Dec-06	Bicara Therapeutics' Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026 BCAX GlobeNewswire
Dec-01	Bicara Therapeutics Announces Publication of an Abstract with Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab in 1L HPV-negative R/M HNSCC at ESMO Asia 2025 BCAX GlobeNewswire
Nov-10	Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update BCAX GlobeNewswire
Oct-13	Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC BCAX GlobeNewswire
Aug-27	Bicara Therapeutics to Participate in Upcoming Investor Conferences BCAX GlobeNewswire
Aug-12	Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update BCAX GlobeNewswire
Jun-03	Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference BCAX GlobeNewswire
Jun-01	Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025 BCAX GlobeNewswire
May-22	Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting BCAX GlobeNewswire
May-13	Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update BCAX GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.